This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).

This study has been terminated.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: May 3, 2012
Last updated: March 22, 2016
Last verified: March 2016
This study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of successive intravenous (IV) doses of LFG316 in eligible patients with neovascular age-related macular degeneration (AMD)

Condition Intervention Phase
Neovascular Age-related Macular Degeneration Drug: Placebo Drug: LFG316 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multiple Dose, Two-cohort Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous LFG316 in Patients With Neovascular Age-related Macular Degeneration

Resource links provided by NLM:

Further study details as provided by Novartis ( Novartis Pharmaceuticals ):

Primary Outcome Measures:
  • Number of anti-vascular endothelial growth factor (anti-VEGF) retreatment vs time [ Time Frame: Day 1 to Day 113 (starting from the day of dosing until the end of the study) ]
    Number of retreatments with anti-VEGF treatments will be recorded.

  • Number and percentage of patients with adverse events. [ Time Frame: Day 1 to Day 113 (starting from the day of dosing until the end of the study) ]
    Adverse events will be determined based on descriptive analyses of vital signs, ECG evaluation, and clinical safety laboratory evaluations. All abnormalities will be flagged and summary statistics will be provided by treatment and visit/time.Will be tabulated by body system and preferred term with a breakdown by treatment.

Secondary Outcome Measures:
  • Effect of LFG316 on visual acuity [ Time Frame: Day 1 to Day 113 ]
    "Early Treatment Diabetic Retinopathy Study" (ETDRS best corrected visual acuity measured under ETDRS conditions). Number of letters correctly read will be recorded.

  • Effect of LFG316 on central retinal thickness, choroidal neovascular membrane area and drusen volume. [ Time Frame: Day 1 to Day 113 ]
    summary statistics will be provided by treatment group, cohort and visit/time. Treatment effect will be assessed by comparison of mean change from baseline to Day 85 of patients who received or did not receive anti-VEGF therapy.

  • Serum concentrations of total LFG316 versus time [ Time Frame: Days 1, 8, 15, 22, 29, 43, 57, 78, 85 and 113 for both cohorts. ]
    Blood samples will be collected.

  • Serum concentration of pharmacodynamic parameters (Weislab and C5) versus time [ Time Frame: screening and Days 1, 8, 15, 22, 29, 43, 57, 78, 85 and 113 (for both cohorts). ]
    Blood samples will be collected.

Enrollment: 1
Study Start Date: December 2012
Study Completion Date: May 2013
Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo Drug: Placebo
Experimental: LFG316: 10 mg/kg (2 doses in cohort 1) Drug: LFG316
Experimental: LFG316: 20 mg/kg (2 doses in cohort 1, 3 doses in cohort 2). Drug: LFG316


Ages Eligible for Study:   55 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

- Active choroidal neovascular AMD in at least one eye.

Exclusion Criteria:

  • Retinal disease other than AMD that, in the investigator's opinion, would interfere with safety or study conduct.
  • Choroidal neovascularization due to a cause other than AMD.
  • In the study eye, media opacity that, in the investigator's opinion, would interfere with study conduct.
  • Any disease or concomitant (or recent) medication expected to cause systemic immunosuppression.
  • History of meningococcal meningitis in the past 10 years, or any history of recurrent meningitis.
  • History of hospitalization for pneumococcal pneumonia within the past 3 years.
  • History of serious systemic infection within the past 12 months.
  • Any of the following treatments to the study eye within 7 days prior to study drug dosing: ranibizumab (Lucentis), bevacizumab (Avastin), pegaptanib (Macugen), or other VEGF inhibitor.

Other protocol-defined inclusion/exclusion criteria may apply

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01624636

United States, Arizona
Novartis Investigative Site
Phoenix, Arizona, United States, 85014
United States, Florida
Novartis Investigative Site
Winter Haven, Florida, United States, 33880
United States, Ohio
Novartis Investigative Site
Beachwood/Cleveland, Ohio, United States, 44122
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Responsible Party: Novartis Pharmaceuticals Identifier: NCT01624636     History of Changes
Other Study ID Numbers: CLFG316A2201
Study First Received: May 3, 2012
Last Updated: March 22, 2016

Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Age-related Macular Degeneration
Neovascular AMD

Additional relevant MeSH terms:
Macular Degeneration
Wet Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases processed this record on September 19, 2017